

Date: 28.08.2014

To,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Fax : 022-22723121/2041/ 1072

National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor,
Plot No. C/1, G block,
Bandra-Kurla Complex,
Bandra (E)

Mumbai - 400 051.

Fax : 022-26598237/38

Ref: Scrip ID - SHARONBIO Scrip Code 532908

Sub: Submission of Financial Results under Clause 41 of the Listing Agreement.

Dear Sir,

Enclosed herewith the Audited Financial results for the Quarter and year ended **30th June, 2014** along with the Auditors Report thereon.

Thanking You.

Yours Faithfully,

For Sharon Bio-Medicine Limited



Mohan Kala
Director

AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED JUNE 30, 2014

SR. NO.	PARTICULARS	STANDALONE				
		Quarter Ended			Year Ended	
		30/06/2014 (Audited)	31/03/2014 (Unaudited)	30/06/2013 (Audited)	30/06/2014 (Audited)	30/06/2013 (Audited)
1	Net Sales / Income from Operations	34,675.87	31,568.54	32,254.18	131,376.83	105,949.65
	Total Income	34,675.87	31,568.54	32,254.18	131,376.83	105,949.65
2	Total Expenditure					
	a) (Increase)/Decrease in Stock in Trade	(3,035.88)	(1,645.70)	(3,665.12)	(6,221.38)	(6,402.08)
	b) Consumption of Materials	26,577.02	21,670.36	26,297.80	94,808.62	76,675.83
	c) Purchases of Trading Goods	5,458.02	6,409.11	5,602.99	22,687.57	19,934.11
	d) Employees Cost	654.29	607.32	508.99	2,307.62	1,851.29
	e) Depreciation	298.70	419.89	386.14	1,535.44	1,203.50
	f) Other Expenditure	593.55	605.76	268.87	2,088.53	1,879.50
	Total	30,545.70	28,066.74	29,399.67	117,206.40	95,142.15
3	Profit from Operations before Exchange Rate Difference, Other Income, Interest & Exceptional Items (1 - 2)	4,130.17	3,501.80	2,854.51	14,170.43	10,807.50
4	Other Income	112.83	15.26	12.78	167.71	88.65
5	Profit from Operations before Interest & Exceptional items (3 + 4)	4,243.00	3,517.06	2,867.29	14,338.14	10,896.15
6	Interest	1,417.92	1,401.03	1,073.13	5,313.78	4,277.19
7	Profit after Interest but before Exception items (5-6)	2,825.08	2,116.03	1,794.16	9,024.36	6,618.96
8	Exception Items	(145.31)	(141.99)	-	548.98	-
9	Profit(+)/Loss(-) from Ordinary Activities before tax (7-8)	2,679.77	1,974.04	1,794.16	8,475.38	6,618.96
10	Tax Expenses	644.52	190.11	345.00	1,513.66	1,333.06
11	Net Profit before ordinary activities (9 - 10)	2,035.25	1,783.93	1,449.16	6,961.72	5,285.90
12	Extra Ordinary Items (Net of Tax)	-	-	-	-	-
13	Net Profit after Taxes (11 - 12)	2,035.25	1,783.93	1,449.16	6,961.72	5,285.90
14	Paid up Equity Share Capital (Face value of Rs.2/- each)	2,111.38	2,111.38	1,055.69	2,111.38	1,055.69
15	Reserves excluding Revaluation Reserves	33,327.88	-	24,169.37	33,327.04	24,169.37
16	Earning Per Shares					
	i) EPS	1.93	1.69	13.73	6.59	50.07
	ii) Diluted EPS	1.36	1.19	10.65	4.65	38.85

Part-II

SR. NO.	PARTICULARS	Quarter Ended			Year Ended	
		30/06/2014 (Audited)	31/03/2014 (Unaudited)	30/06/2013 (Audited)	30/06/2014 (Audited)	30/06/2013 (Audited)
(A)	Aggregate of Public Shareholdings					
	No. of Shares	42,012,258	42,017,020	4,194,125	42,012,258	4,194,125
	Percentage of Shareholdings	39.80%	39.80%	39.73%	39.80%	39.73%
17	Promoters & promoter group Shareholding					
	a) Pledged / Encumbered					
	- Number of Shares	5,000,000	NIL	327,500	5,000,000	327,500
	- Percentage of Shares	7.94%	NIL	5.15%	7.94%	5.15%
	(as a % of the total shareholding of promoter & promoter group)					
	- Percentage of Shares	4.73%	NIL	3.10%	4.73%	3.10%
	(as a % of the total share capital of the Company)					
	b) Non-encumbered					
	- Number of Shares	63,556,742	62,551,980	6,035,275	63,556,742	6,035,275
	- Percentage of Shares	92.60%	100.00%	94.85%	92.60%	94.85%
	(as a % of the total shareholding of promoter & promoter group)					
	- Percentage of Shares	55.47%	60.20%	57.17%	55.47%	57.17%
	(as a % of the total share capital of the Company)					

NOTES :-

Audited Standalone Statement of Assets and Liabilities as at 30th June, 2014

Particulars	(Rs. in Lacs)	
	Year Ended on 30/06/2014	Year Ended on 30/06/2013
Shareholders' funds		
(a) Capital	2,111.38	1,055.69
(b) Reserves and Surplus	32,282.88	23,337.04
Loan Funds	72,538.36	64,388.81
Deferred tax liabilities (net)	1,045.00	832.33
Total	107,977.62	89,613.87
Fixed Assets	33,994.67	31,436.20
Investments	123.24	398.23
Current assets, loans and advances		
(a) Inventories	32,245.02	26,023.64
(b) Sundry debtors	41,431.08	35,509.89
(c) Cash and bank balance	1,227.33	627.34
(d) Loans and advances	7,070.30	3,198.11
	81,973.73	65,358.98
Less: Current Liabilities and Provisions		
(a) Liabilities	6,315.44	6,141.33
(b) Provisions	1,798.58	1,438.21
	8,114.02	7,579.54
Net Current Assets	73,859.71	57,779.44
Miscellaneous Expenditure (not written off or adjusted)	-	-
PROFIT AND LOSS ACCOUNT		
Total	107,977.62	89,613.87
	-	-

- 1) The above results for the quarter ended June 30, 2014 have been reviewed by the Audit Committee and were taken on record by the Board of Directors in its meeting held on August 28, 2014.
- 2) The "Limited Review" required under clause 41 of listing agreement has been done by statutory auditors of the Company.
- 3) The Company has provided for Foreign Exchange (Loss)/Gains under Exception Items due to exchange differences arising during the period(s) on foreign currency contracts and borrowings including Foreign Currency Convertible Bonds.
- 4) Shares has been split in the ratio of 1 : 5, subdividing the face value of Share to Rs 2/- from Rs. 10/- during the Quarter ended March, 2014.
- 5) Company has issued Bonus Shares in the ratio of 1 : 1 during the quarter ended March, 2014.
- 6) Previous years figures have been regrouped and recast wherever necessary.
- 7) Information on investor complaints for the quarter ended June 30, 2014 (In Nos.)

Opening Balance of Complaints	Received during the Quarter	Disposed off during the Quarter
NIL	0	0

For Sharon Bio-Medicine Ltd.

Place : Mumbai.
Date : 28.08.2014

Savita
Savita Gowda
Managing Director.

AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED JUNE 30, 2014

SR. NO.	PARTICULARS	CONSOLIDATED				
		Quarter Ended			Year Ended	
		30/06/2014 (Audited)	31/03/2014 (Unaudited)	30/06/2013 (Audited)	30/06/2014 (Audited)	30/06/2013 (Audited)
1	Net Sales / Income from Operations	34,951.87	31,848.54	32,526.12	132,479.28	107,351.53
	Total Income	34,951.87	31,848.54	32,526.12	132,479.28	107,351.53
2	Total Expenditure					
	a) (Increase)/Decrease in Stock in Trade	(3,035.88)	(1,645.70)	(3,665.12)	(6,221.38)	(6,402.08)
	b) Consumption of Materials	26,577.02	21,670.36	26,297.80	94,808.62	76,675.83
	c) Purchases of Trading Goods	5,713.02	6,665.11	5,821.99	23,708.35	20,842.05
	d) Employees Cost	656.84	609.67	516.04	2,336.17	1,861.29
	e) Depreciation	298.70	419.89	386.14	1,535.44	1,212.78
	f) Other Expenditure	595.53	607.54	271.17	2,096.51	2,270.99
	Total	30,805.23	28,326.87	29,628.02	118,263.71	96,460.86
3	Profit from Operations before Exchange Rate Difference, Other Income, Interest & Exceptional Items (1 - 2)	4,146.64	3,521.67	2,898.10	14,215.57	10,890.67
4	Other Income	115.33	17.76	12.78	193.34	119.00
5	Profit from Operations before Interest & Exceptional items (3 + 4)	4,261.97	3,539.43	2,910.88	14,408.91	11,009.67
6	Interest	1,417.92	1,401.03	1,073.13	5,314.02	4,306.13
7	Profit after Interest but before Exception items (5-6)	2,844.05	2,138.40	1,837.75	9,094.89	6,703.54
8	Exception Items	(145.31)	(141.99)	-	548.98	-
9	Profit(+)/Loss(-) from Ordinary Activities before tax (7-8)	2,698.74	1,996.41	1,837.75	8,545.91	6,703.54
10	Tax Expenses	644.52	190.11	345.00	1,513.66	1,333.06
11	Net Profit before ordinary activities (9 - 10)	2,054.22	1,806.30	1,492.75	7,032.25	5,370.48
12	Extra Ordinary Items (Net of Tax)					
13	Net Profit after Taxes (11 - 12)	2,054.22	1,806.30	1,492.75	7,032.25	5,370.48
14	Paid up Equity Share Capital (Face value of Rs.2/- each)	2,111.38	2,111.38	1,055.69	2,111.38	1,055.69
15	Reserves excluding Revaluation Reserves	34,164.19	-	24,102.60	34,164.19	24,102.60
16	Earning Per Shares					
	i) EPS	1.95	1.71	14.14	6.66	50.87
	ii) Diluted EPS	1.37	1.21	10.97	4.70	39.47

Part -II

SR. NO.	PARTICULARS	Quarter Ended			Year Ended	
		30/06/2014 (Audited)	31/03/2014 (Unaudited)	30/06/2013 (Audited)	30/06/2014 (Audited)	30/06/2013 (Audited)
(A)	Aggregate of Public Shareholdings					
	No. of Shares	42,012,258	42,017,020	4,194,125	42,012,258	4,194,125
	Percentage of Shareholdings	39.80%	39.80%	39.73%	39.80%	39.73%
17	Promoters & promoter group Shareholding					
	a) Pledged / Encumbered					
	- Number of Shares	5,000,000	NIL	327,500	5,000,000	327,500
	- Percentage of Shares	7.94%	NIL	5.15%	7.94%	5.15%
	(as a % of the total shareholding of promoter & promoter group)					
	- Percentage of Shares	4.73%	NIL	3.10%	4.73%	3.10%
	(as a % of the total share capital of the Company)					
	b) Non-encumbered					
	- Number of Shares	63,556,742	62,551,980	6,035,275	63,556,742	6,035,275
	- Percentage of Shares	92.60%	100.00%	94.85%	92.60%	94.85%
	(as a % of the total shareholding of promoter & promoter group)					
	- Percentage of Shares	55.47%	60.20%	57.17%	55.47%	57.17%
	(as a % of the total share capital of the Company)					

NOTES :-

Audited Consolidated Statement of Assets and Liabilities as at 30th June, 2014

Particulars	CONSOLIDATED	
	Year Ended on 30/06/2014	Year Ended on 30/06/2013
Shareholders' funds		
(a) Capital	2,111.38	1,120.24
(b) Reserves and Surplus	33,119.19	24,102.60
Loan Funds	72,538.37	64,397.20
Deferred tax liabilities (net)	1,045.00	832.33
Total	108,813.94	90,452.37
Fixed Assets	33,994.67	31,436.20
Investments	58.69	398.23
Current assets, loans and advances	32,245.02	26,023.64
(a) Inventories	42,261.04	36,351.91
(b) Sundry debtors	1,234.30	631.82
(c) Cash and bank balance	7,153.28	3,210.57
(d) Loans and advances	82,893.64	66,217.94
Less: Current Liabilities and Provisions	6,334.48	6,161.79
(a) Liabilities	1,798.58	1,438.21
(b) Provisions	8,133.06	7,600.00
Net Current Assets	74,760.58	58,617.94
Miscellaneous Expenditure (not writtenoff or adjusted)	-	-
PROFIT AND LOSS ACCOUNT	108,813.94	90,452.37
Total	-	-

- 1) The above results for the quarter ended June 30, 2014 have been reviewed by the Audit Committee and were taken on record by the Board of Directors in its meeting held on August 28, 2014.
- 2) The "Limited Review" required under clause 41 of listing agreement has been done by statutory auditors of the Company.
- 3) The Company has provided for Foreign Exchange (Loss)/Gains under Exception Items due to exchange differences arising during the period(s) on foreign currency contracts and borrowings including Foreign Currency Convertible Bonds.
- 4) Shares has been split in the ratio of 1 : 5, subdividing the face value of Share to Rs 2/- from Rs. 10/- during the Quarter ended March, 2014.
- 5) Company has issued Bonus Shares in the ratio of 1 : 1 during the quarter ended March, 2014.
- 6) Previous years figures have been regrouped and recast wherever necessary.
- 7) Information on investor complaints for the quarter ended June 30, 2014 (In Nos.)

Opening Balance of Complaints	Closing Balance
NIL	NIL

For Sharon Bio-Medicine Ltd.

Navita
Savita Gowda
Managing Director.

Place : Mumbai.
Date : 28.08.2014